Matinas BioPharma (MTNB) 10-Q 13 Nov 24 2024 Q3 Quarterly report Financial data

Cover

Cover - $ / shares	9 Months Ended
	Sep. 30, 2024	Nov. 13, 2024
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Sep. 30, 2024
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2024
Current Fiscal Year End Date	--12-31
Entity File Number	001-38022
Entity Registrant Name	MATINAS BIOPHARMA HOLDINGS, INC.
Entity Central Index Key	0001582554
Entity Tax Identification Number	46-3011414
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	1545 Route 206 South
Entity Address, Address Line Two	Suite 302
Entity Address, City or Town	Bedminster
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07921
City Area Code	908
Local Phone Number	484-8805
Title of 12(b) Security	Common Stock
Trading Symbol	MTNB
Security Exchange Name	NYSEAMER
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,086,985
Entity Listing, Par Value Per Share	$ 0.0001

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Sep. 30, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents		$ 10,295	$ 4,787
Marketable debt securities		500	8,969
Restricted cash – security deposit		50	50
Prepaid expenses and other current assets		896	1,737
Total current assets		11,741	15,543
Non-current assets:
Leasehold improvements and equipment – net		1,648	1,923
Operating lease right-of-use assets – net		2,618	3,064
Finance lease right-of-use assets – net		17	21
In-process research and development		3,017	3,017
Goodwill		1,336	1,336
Restricted cash – security deposit		200	200
Total non-current assets		8,836	9,561
Total assets		20,577	25,104
Current liabilities:
Accounts payable		349	514
Accrued expenses		1,037	1,447
Operating lease liabilities – current		733	656
Financing lease liabilities – current		5	5
Total current liabilities		2,124	2,622
Non-current liabilities:
Deferred tax liability		341	341
Operating lease liabilities – net of current portion		2,319	2,877
Financing lease liabilities – net of current portion		14	18
Total non-current liabilities		2,674	3,236
Total liabilities		4,798	5,858
Stockholders’ equity:
Common stock par value $0.0001 per share, 250,000,000 shares authorized at September 30, 2024 and December 31, 2023; 5,086,985 and 4,345,291 issued and outstanding as of September 30, 2024 and December 31, 2023, respectively	[1]	1
Additional paid-in capital		207,169	195,040
Accumulated deficit		(191,391)	(175,573)
Accumulated other comprehensive loss			(221)
Total stockholders’ equity		15,779	19,246
Total liabilities and stockholders’ equity		$ 20,577	$ 25,104
[1]Adjusted to reflect the impact of the 1-for-50 reverse stock split

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Aug. 30, 2024	Sep. 30, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Common stock, par value		$ 0.0001	$ 0.0001
Common Stock, Shares Authorized		250,000,000	250,000,000
Common stock shares issued		5,086,985	4,345,291
Common stock shares outstanding		5,086,985	4,345,291
Stockholders' equity, reverse stock split	1-for-50 reverse stock split

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue:
Contract revenue					$ 1,096
Costs and expenses:
Research and development		2,239	3,295	9,057	10,824
General and administrative		2,142	2,839	7,067	8,151
Total costs and expenses		4,381	6,134	16,124	18,975
Loss from operations		(4,381)	(6,134)	(16,124)	(17,879)
Other income, net		106	79	306	251
Net loss		$ (4,275)	$ (6,055)	$ (15,818)	$ (17,628)
Net loss per share - basic	[1]	$ (0.85)	$ (1.39)	$ (3.30)	$ (4.06)
Net loss per share - diluted	[1]	$ (0.85)	$ (1.39)	$ (3.30)	$ (4.06)
Weighted average common shares outstanding:
Weighted average common shares outstanding - basic	[1]	5,037,829	4,345,291	4,791,572	4,345,291
Weighted average common shares outstanding - diluted	[1]	5,037,829	4,345,291	4,791,572	4,345,291
Other comprehensive gain, net of tax
Unrealized gain on securities available-for-sale		$ 51	$ 155	$ 221	$ 465
Other comprehensive gain, net of tax		51	155	221	465
Comprehensive loss		$ (4,224)	$ (5,900)	$ (15,597)	$ (17,163)
[1]Basic and diluted net loss per common share and basic and diluted weighted average common shares outstanding used in computing basic and diluted loss per common share for the three and nine months ended September 30, 2024 and 2023 have been adjusted to reflect the impact of the 1-for-50 reverse stock split

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) (Parenthetical)	Aug. 30, 2024
Income Statement [Abstract]
Stockholders' equity, reverse stock split	1-for-50 reverse stock split

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($) $ in Thousands		Common Stock [Member]		Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance at Dec. 31, 2022			[1]	$ 190,092	$ (152,631)	$ (824)	$ 36,637
Balance, shares at Dec. 31, 2022	[1]	4,345,291
Stock-based compensation			[1]	3,676			3,676
Other comprehensive income			[1]			465	465
Net loss			[1]		(17,628)		(17,628)
Balance at Sep. 30, 2023			[1]	193,768	(170,259)	(359)	23,150
Balance, shares at Sep. 30, 2023	[1]	4,345,291
Balance at Jun. 30, 2023			[1]	192,572	(164,204)	(514)	27,854
Balance, shares at Jun. 30, 2023	[1]	4,345,291
Stock-based compensation			[1]	1,196			1,196
Other comprehensive income			[1]			155	155
Net loss			[1]		(6,055)		(6,055)
Balance at Sep. 30, 2023			[1]	193,768	(170,259)	(359)	23,150
Balance, shares at Sep. 30, 2023	[1]	4,345,291
Balance at Dec. 31, 2023			[1]	195,040	(175,573)	(221)	19,246
Balance, shares at Dec. 31, 2023	[1]	4,345,291
Stock-based compensation			[1]	2,951			2,951
Issuance of common stock and warrants in public offering, net of stock issuance cost		$ 1	[1]	9,178			9,179
Issuance of common stock and warrants in public offering, net, shares	[1]	671,033
Issuance of common stock in reverse stock split			[1]
Issuance of common stock in reverse stock split, shares	[1]	70,661
Other comprehensive income			[1]			221	221
Net loss			[1]		(15,818)		(15,818)
Balance at Sep. 30, 2024		$ 1	[1]	207,169	(191,391)		15,779
Balance, shares at Sep. 30, 2024	[1]	5,086,985
Balance at Jun. 30, 2024		$ 1	[1]	206,269	(187,116)	(51)	19,103
Balance, shares at Jun. 30, 2024	[1]	5,016,324
Stock-based compensation			[1]	965			965
Issuance of common stock and warrants in public offering, net of stock issuance cost			[1]	(65)			(65)
Issuance of common stock in reverse stock split			[1]
Issuance of common stock in reverse stock split, shares	[1]	70,661
Other comprehensive income			[1]			51	51
Net loss			[1]		(4,275)		(4,275)
Balance at Sep. 30, 2024		$ 1	[1]	$ 207,169	$ (191,391)		$ 15,779
Balance, shares at Sep. 30, 2024	[1]	5,086,985
[1]Adjusted to reflect the impact of the 1-for-50 reverse stock split

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Stockholders' Equity (Unaudited) (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2024
Statement of Stockholders' Equity [Abstract]
Stock issuance cost	$ 65	$ 877	[1]
[1]Adjusted to reflect the impact of the 1-for-50 reverse stock split

Condensed Consolidated Statem_5

Condensed Consolidated Statements of Cash Flow (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (15,818)	$ (17,628)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	275	288
Stock based compensation expense	2,951	3,676
Amortization of operating lease right-of-use assets	446	406
Amortization of finance lease right-of-use assets	4	7
Amortization of bond (premium)/discount	(16)	90
Changes in operating assets and liabilities:
Operating lease liabilities	(481)	(411)
Prepaid expenses and other current assets	839	3,996
Accounts payable	(165)	217
Accrued expenses and other liabilities	(410)	(1,340)
Net cash used in operating activities	(12,375)	(10,699)
Cash flows from investing activities:
Purchase of marketable debt securities	(8,437)
Proceeds from maturities of marketable debt securities	17,145	10,500
Purchases of leasehold improvements and equipment		(218)
Net cash provided by investing activities	8,708	10,282
Cash flows from financing activities:
Net proceeds from public offerings of common stock and warrants	9,179
Payments of finance lease liability – principal	(4)	(6)
Net cash provided by/(used in) financing activities	9,175	(6)
Net increase/(decrease) in cash, cash equivalents and restricted cash	5,508	(423)
Cash, cash equivalents and restricted cash at beginning of period	5,037	7,080
Cash, cash equivalents and restricted cash at end of period	10,545	6,657
Supplemental non-cash financing and investing activities:
Unrealized gain on marketable debt securities	$ 221	$ 465

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Pay vs Performance Disclosure [Table]
Net Income (Loss)	$ (4,275)	$ (6,055)	$ (15,818)	$ (17,628)

Insider Trading Arrangements

Insider Trading Arrangements	9 Months Ended
	Sep. 30, 2024
Insider Trading Arrangements [Line Items]
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Description of Business

Description of Business	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business	Note 1 – Description of Business Matinas BioPharma Holdings Inc. (“Holdings”) is a Delaware corporation formed in 2013. Holdings is the parent company of Matinas BioPharma, Inc. (“BioPharma”), and Matinas BioPharma Nanotechnologies, Inc. (“Nanotechnologies,” formerly known as Aquarius Biotechnologies, Inc.), its operating subsidiaries (“Nanotechnologies”, and together with “Holdings” and “BioPharma”, “the Company”). The Company is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products.

Liquidity, Plan of Operations a

Liquidity, Plan of Operations and Going Concern	9 Months Ended
	Sep. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Liquidity, Plan of Operations and Going Concern	Note 2 – Liquidity, Plan of Operations and Going Concern The Company has experienced net losses and negative cash flows from operations each period since its inception. Through September 30, 2024, the Company had an accumulated deficit of $ 191,391 15,818 The Company has been engaged in developing its lipid nanocrystal (“LNC”) platform delivery technology and a pipeline of associated product candidates, including MAT2203, since 2011. To date, the Company has not obtained regulatory approval for any of its product candidates nor generated any revenue from product sales, and the Company expects to incur significant expenses to complete development of its product candidates. The Company may never be able to obtain regulatory approval for the marketing of any of its product candidates in any indication in the United States or internationally and there can be no assurance that the Company will generate revenues or ever achieve profitability. If the Company obtains U.S. Food and Drug Administration (“FDA”) approval for one or more of its product candidates, the Company expects that its expenses will continue to increase once the Company reaches commercial launch. The Company also expects that its research and development expenses will continue to increase as it moves forward with additional clinical studies for its current product candidates and development of additional product candidates. As a result, the Company expects to continue to incur substantial losses for the foreseeable future, and that these losses will be increasing. As of September 30, 2024, the Company had cash and cash equivalents of $ 10,295 500 250 The ability of the Company to continue as a going concern is dependent upon control over its operating expenses, anticipated proceeds from future sales of common stock through its At-The-Market Sales Agreement (“ATM”) with BTIG, LLC. and securing additional financing. While the Company believes in the viability of this strategy and believes the actions presently being taken by the Company provide the opportunity for it to continue as a going concern, there can be no assurance the Company will be successful in its implementation. In particular, utilization of the ATM may not be viable due to market conditions and new financing may not be available on acceptable terms, or at all. These consolidated financial statements do not include any adjustments related to the recoverability and classification of asset amounts or the amounts and classification of liabilities that might be necessary if the Company is unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 3 – Summary of Significant Accounting Policies Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Company’s management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company’s financial statements. Reverse Stock Split On August 30, 2024, the Company effected a 1-for-50 reverse stock split Stockholders’ Equity

Cash, Cash Equivalents, Restric

Cash, Cash Equivalents, Restricted Cash and Marketable Debt Securities	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Cash, Cash Equivalents, Restricted Cash and Marketable Debt Securities	Note 4 – Cash, Cash Equivalents, Restricted Cash and Marketable Debt Securities The Company considers all highly liquid financial instruments with original maturities of three months or less when purchased to be cash and cash equivalents and all investments with maturities of greater than three months from date of purchase are classified as marketable debt securities. Cash and cash equivalents consist of cash in bank checking and savings accounts, money market funds and short-term U.S. treasury bonds that mature within three months of settlement date. Cash, Cash Equivalents and Restricted Cash The Company presents restricted cash with cash and cash equivalents in the Condensed Consolidated Statements of Cash Flows. Restricted cash at both September 30, 2024 and December 31, 2023 of $ 250 The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of September 30, 2024, December 31, 2023, September 30, 2023 and December 31, 2022: Schedule of Cash, Cash Equivalents and Restricted Cash September 30, 2024 December 31, 2023 September 30, 2023 December 31, 2022 Cash and cash equivalents $ 10,295 $ 4,787 $ 6,407 $ 6,830 Restricted cash included in current/non-current assets 250 250 250 250 Cash, cash equivalents and restricted cash in the statement of cash flows $ 10,545 $ 5,037 $ 6,657 $ 7,080 Marketable Debt Securities The Company has classified its investments in marketable debt securities as available-for-sale and as a current asset. The Company’s investments in marketable debt securities are carried at fair value, with unrealized gains and losses included as a separate component of stockholders’ equity. Unrealized losses and gains are classified as other comprehensive (loss)/income and costs are determined on a specific identification basis. Realized gains and losses from our marketable debt securities are recorded in other income, net. The Company did not incur any realized gains and losses during the three and nine months ended September 30, 2024 and 2023. For the three and nine months ended September 30, 2024, the Company recorded unrealized gains of $ 51 221 155 465 0 221 The following tables summarize the Company’s marketable debt securities as of September 30, 2024: Schedule of Marketable Debt Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value Corporate Debt Securities $ 500 $ — $ — $ 500 Total marketable debt securities $ 500 $ — $ — $ 500 All debt securities classified as available-for-sale are due to mature within one year of September 30, 2024. The following tables summarize the Company’s marketable debt securities as of December 31, 2023: Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 999 $ — $ (3 ) $ 996 U.S. Government Notes 8,191 — (218 ) 7,973 Total marketable debt securities $ 9,190 $ — $ (221 ) $ 8,969 All debt securities classified as available-for-sale are due to mature within one year of December 31, 2023.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurements	Note 5 - Fair Value Measurements The Company uses the fair value hierarchy to measure the value of its financial instruments. The fair value hierarchy is based on inputs to valuation techniques that are used to measure fair value that are either observable or unobservable. Observable inputs reflect assumptions market participants would use in pricing an asset or liability based on market data obtained from independent sources, while unobservable inputs reflect a reporting entity’s pricing based upon its own market assumptions. The basis for fair value measurements for each level within the hierarchy is described below: ● Level 1 – Quoted prices for identical assets or liabilities in active markets. ● Level 2 – Quoted prices for identical or similar assets and liabilities in markets that are not active; or other model-derived valuations whose inputs are directly or indirectly observable or whose significant value drivers are observable. ● Level 3 – Valuations derived from valuation techniques in which one or more significant inputs to the valuation model are unobservable and for which assumptions are used based on management estimates. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. The carrying amounts of cash equivalents, current portion of restricted cash, prepaid expenses and other current assets, accounts payable, current portion of lease liabilities and accrued expenses approximate fair value due to the short-term nature of these instruments. A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities September 30, 2024 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy September 30, 2024 Total (Level 1) (Level 2) (Level 3) Assets Marketable Debt Securities: Corporate Debt Securities $ 500 $ — $ 500 $ — Total $ 500 $ — $ 500 $ — December 31, 2023 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy December 31, 2023 Total (Level 1) (Level 2) (Level 3) Assets Marketable Debt Securities: U.S. Treasury Bonds $ 996 $ 996 $ — $ — U.S. Government Notes 7,973 — 7,973 — Total $ 8,969 $ 996 $ 7,973 $ — U.S. treasury bonds are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices for identical assets in active markets. Marketable debt securities consisting of U.S. government notes and corporate debt securities are classified as Level 2 and are valued using quoted market prices in markets that are not active.

Leasehold Improvements and Equi

Leasehold Improvements and Equipment	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Leasehold Improvements and Equipment	Note 6 – Leasehold Improvements and Equipment Leasehold improvements and equipment, summarized by major category, consist of the following as of September 30, 2024 and December 31, 2023: Schedule of Leasehold Improvements and Equipment September 30, 2024 December 31, 2023 Equipment $ 2,463 $ 2,463 Leasehold improvements 1,155 1,155 Total 3,618 3,618 Leasehold improvements and equipment, gross 3,618 3,618 Less: accumulated depreciation and amortization 1,970 1,695 Leasehold improvements and equipment, net $ 1,648 $ 1,923 Depreciation and amortization expense for the three and nine months ended September 30, 2024 was $ 90 275 98 288 218

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Accrued Expenses and Other Liabilities	Note 7 – Accrued Expenses and Other Liabilities Accrued Expenses, summarized by major category, as of September 30, 2024 and December 31, 2023 consist of the following: Schedule of Accrued Expenses September 30, 2024 December 31, 2023 Payroll and incentives $ 720 $ 1,176 General and administrative expenses 299 196 Research and development expenses 18 75 Total $ 1,037 $ 1,447

Leases

Leases	9 Months Ended
	Sep. 30, 2024
Leases
Leases	Note 8 – Leases The Company has various lease agreements, including leases of office space, a laboratory and manufacturing facility, and various equipment. Some leases include purchase, termination or extension options for one or more years. The assets and liabilities from operating and finance leases are recognized at the lease commencement date based on the present value of remaining lease payments over the lease term using the Company’s incremental borrowing rates or implicit rates, when readily determinable. Short-term leases, which have an initial term of 12 Operating lease obligations The Company incurred lease expense for its operating leases of $ 225 677 152 139 446 406 Finance Leases The Company incurred interest expense on its finance leases of $ 1 2 0 2 1 4 2 7 The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of September 30, 2024: Schedule of Maturity of Operating and Finance Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2024 $ 245 $ 2 2025 998 7 2026 1,040 7 2027 944 7 2028 273 — Thereafter 138 — 2028 - - Thereafter - — Total undiscounted operating lease payments $ 3,638 $ 23 Less: Imputed interest 586 4 Present value of operating lease liabilities $ 3,052 $ 19 Weighted average remaining lease term in years 3.6 3.1 Weighted average discount rate 9.2 % 11.6 % The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2023: Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2024 $ 956 $ 7 2025 998 7 2026 1,040 7 2027 944 7 2028 273 — Thereafter 138 - Total undiscounted operating lease payments $ 4,349 $ 28 Less: Imputed interest 816 5 Present value of operating lease liabilities $ 3,533 $ 23 Weighted average remaining lease term in years 4.3 3.9 Weighted average discount rate 9.2 % 11.6 %

Revenue Recognition, Collaborat

Revenue Recognition, Collaboration Agreements and Other	9 Months Ended
	Sep. 30, 2024
Revenue Recognition Collaboration Agreements And Other
Revenue Recognition, Collaboration Agreements and Other	Note 9 – Revenue Recognition, Collaboration Agreements and Other The Company did not enter into any revenue recognition or collaboration agreements during the nine months ended September 30, 2024. BioNTech Research Collaboration On April 8, 2022, the Company entered into the BioNTech Agreement to evaluate the combination of mRNA formats utilizing the Company’s proprietary LNC platform delivery technology. Under the terms of the BioNTech Agreement, the Company received an exclusivity fee in the amount of $ 2,750 The $ 2,750 During the first quarter of 2023, $ 688 375 Genentech Feasibility Study Agreement On December 12, 2019, the Company entered into the Genentech Agreement which involves the development of oral formulations using the Company’s LNC platform delivery technology. Under the terms of the Genentech Agreement, Genentech paid the Company a total of $ 100 33

Stockholders_ Equity

Stockholders’ Equity	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Stockholders’ Equity	Note 10 – Stockholders’ Equity Common Stock On August 30, 2024, the Company effected the Reverse Stock Split. Accordingly, each of the Company’s stockholders received one share of the Company’s common stock for every 50 shares of the Company’s common stock that such stockholder held immediately prior to the effective time of the Reverse Stock Split. The Reverse Stock Split affected all of the Company’s issued and outstanding shares of common stock equally provided that no fractional shares of common stock were issued as a result of the Reverse Stock Split as fractional shares of common stock were rounded up to the nearest whole share. The Reverse Stock Split also affected the Company’s outstanding stock-based awards, warrants and other exercisable or convertible securities and resulted in the shares of common stock underlying such instruments being reduced and the exercise price or conversion price being increased proportionally by the Reverse Stock Split ratio. As a result of the Reverse Stock Split, the number of shares of common stock authorized for issuance was adjusted from 500,000,000 250,000,000 0.0001 250,816,164 5,086,985 For the nine months ended September 30, 2024, the Company sold 671,033 666,667 666,667 15.00 10,000 9,190 4,366 54 The Company did not sell any shares of its common stock during the nine months ended September 30, 2023. Warrants As of September 30, 2024, the Company had outstanding warrants to purchase 666,667 17.50 The warrants are exercisable six months after issuance date, April 5, 2024, and have a five-year The following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024: Schedule of Shareholder Equity Warrants Outstanding Shares Outstanding at December 31, 2023 - Issued 666,667 Exercised - Tendered - Expired - Outstanding at September 30, 2024 666,667 Basic and diluted net loss per common share Net loss per share information is determined using the two-class method, which includes the weighted-average number of shares of common stock outstanding during the period and other securities. Under the two-class method, basic net loss per share attributable to common stockholders is computed by dividing the net income attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share attributable to common stockholders is computed using the more dilutive of (1) the two-class method or (2) the if-converted method. During the three and nine months ended September 30, 2024 and 2023, diluted loss per common share is the same as basic loss per common share because, as the Company incurred a net loss during each period presented, the potentially dilutive securities from the assumed exercise of all outstanding stock options and warrants, would have an anti-dilutive effect. The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share because including them would have been anti-dilutive as of September 30, 2024 and 2023: Schedule of Anti-dilutive Securities Excluded from Computation of Earning Per Share As of September 30, 2024 2023 Stock options 872,063 664,689 Warrants 666,667 — Total 1,538,730 664,689

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Accumulated Other Comprehensive Loss	Note 11 – Accumulated Other Comprehensive Loss The following table summarizes the changes in accumulated other comprehensive loss by component during the nine months ended September 30, 2024 and 2023: Schedule of Components of Accumulated Other Comprehensive Loss Net Unrealized Gain/(Loss) on Available-for-Sale Securities Accumulated Other Comprehensive Loss Balance, December 31, 2023 $ (221 ) $ (221 ) Net unrealized gain on securities available-for-sale 221 221 Balance, September 30, 2024 $ — $ — Balance, December 31, 2022 $ (824 ) $ (824 ) Net unrealized gain on securities available-for-sale 465 465 Balance, September 30, 2023 $ (359 ) $ (359 ) All components of accumulated other comprehensive income are net of tax.

Stock-based Compensation

Stock-based Compensation	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Stock-based Compensation	Note 12 – Stock-based Compensation The Company’s Amended and Restated 2013 Equity Compensation Plan (the “Plan”), which expired on May 7, 2024, provided for the granting of incentive stock options, nonqualified stock options, restricted stock units, performance units, and stock purchase rights. There were no significant modifications to the Plan during the nine month periods ended September 30, 2024 and 2023. The term of the Plan was for 10 years. As of September 30, 2024, there were 965,678 The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and Development $ 387 $ 507 $ 1,212 $ 1,576 General and Administrative 578 689 1,739 2,100 Total $ 965 $ 1,196 $ 2,951 $ 3,676 As of September 30, 2024, total compensation costs related to unvested awards not yet recognized was $ 4,597 2.2 Stock Options The following table summarizes the activity for Company’ stock options for the nine months ended September 30, 2024: Schedule of Stock Option Activity Stock Options Outstanding at December 31, 2023 934,243 Granted — Exercised — Forfeited (18,649 ) Expired (43,531 ) Outstanding at September 30, 2024 872,063

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2024
Subsequent Events [Abstract]
Subsequent Events	Note 13 – Subsequent Events On October 31, 2024, the Company announced that negotiations under a previously disclosed non-binding term sheet regarding global rights to MAT2203 have been terminated following notification from the prospective partner. As a result, the Company implemented an 80% workforce reduction effective on that date and ceased all product development. The severance cost associated with this initiative, which will be settled in cash, totaled approximately $ 2,150

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2024
Accounting Policies [Abstract]
Basis of presentation and principles of consolidation	Basis of presentation and principles of consolidation The accompanying unaudited condensed consolidated financial statements include the consolidated accounts of Holdings and its wholly owned subsidiaries, BioPharma, and Nanotechnologies. The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and reflect the operations of the Company and its wholly owned subsidiaries. All intercompany transactions have been eliminated in consolidation. The Company’s significant accounting policies are described in Note 3 within the Company’s Notes to Consolidated Financial Statements included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023. The Company’s management has considered all recent accounting pronouncements issued and believes that these recent pronouncements will not have a material effect on the Company’s financial statements.
Reverse Stock Split	Reverse Stock Split On August 30, 2024, the Company effected a 1-for-50 reverse stock split Stockholders’ Equity

Cash, Cash Equivalents, Restr_2

Cash, Cash Equivalents, Restricted Cash and Marketable Debt Securities (Tables)	9 Months Ended
	Sep. 30, 2024
Cash and Cash Equivalents [Abstract]
Schedule of Cash, Cash Equivalents and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents and restricted cash reported in the Condensed Consolidated Balance Sheets to the total of the amounts in the Condensed Consolidated Statements of Cash Flows as of September 30, 2024, December 31, 2023, September 30, 2023 and December 31, 2022: Schedule of Cash, Cash Equivalents and Restricted Cash September 30, 2024 December 31, 2023 September 30, 2023 December 31, 2022 Cash and cash equivalents $ 10,295 $ 4,787 $ 6,407 $ 6,830 Restricted cash included in current/non-current assets 250 250 250 250 Cash, cash equivalents and restricted cash in the statement of cash flows $ 10,545 $ 5,037 $ 6,657 $ 7,080
Schedule of Marketable Debt Securities	The following tables summarize the Company’s marketable debt securities as of September 30, 2024: Schedule of Marketable Debt Securities Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value Corporate Debt Securities $ 500 $ — $ — $ 500 Total marketable debt securities $ 500 $ — $ — $ 500 Amortized Unrealized Unrealized Cost Gain (Loss) Fair Value U.S. Treasury Bonds $ 999 $ — $ (3 ) $ 996 U.S. Government Notes 8,191 — (218 ) 7,973 Total marketable debt securities $ 9,190 $ — $ (221 ) $ 8,969

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2024
Fair Value Disclosures [Abstract]
Schedule of Fair Value Measurement of Assets and Liabilities	A summary of the assets and liabilities carried at fair value in accordance with the hierarchy defined above is as follows: Schedule of Fair Value Measurement of Assets and Liabilities September 30, 2024 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy September 30, 2024 Total (Level 1) (Level 2) (Level 3) Assets Marketable Debt Securities: Corporate Debt Securities $ 500 $ — $ 500 $ — Total $ 500 $ — $ 500 $ — December 31, 2023 Total (Level 1) (Level 2) (Level 3) Fair Value Hierarchy December 31, 2023 Total (Level 1) (Level 2) (Level 3) Assets Marketable Debt Securities: U.S. Treasury Bonds $ 996 $ 996 $ — $ — U.S. Government Notes 7,973 — 7,973 — Total $ 8,969 $ 996 $ 7,973 $ —

Leasehold Improvements and Eq_2

Leasehold Improvements and Equipment (Tables)	9 Months Ended
	Sep. 30, 2024
Property, Plant and Equipment [Abstract]
Schedule of Leasehold Improvements and Equipment	Leasehold improvements and equipment, summarized by major category, consist of the following as of September 30, 2024 and December 31, 2023: Schedule of Leasehold Improvements and Equipment September 30, 2024 December 31, 2023 Equipment $ 2,463 $ 2,463 Leasehold improvements 1,155 1,155 Total 3,618 3,618 Leasehold improvements and equipment, gross 3,618 3,618 Less: accumulated depreciation and amortization 1,970 1,695 Leasehold improvements and equipment, net $ 1,648 $ 1,923

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	9 Months Ended
	Sep. 30, 2024
Payables and Accruals [Abstract]
Schedule of Accrued Expenses	Accrued Expenses, summarized by major category, as of September 30, 2024 and December 31, 2023 consist of the following: Schedule of Accrued Expenses September 30, 2024 December 31, 2023 Payroll and incentives $ 720 $ 1,176 General and administrative expenses 299 196 Research and development expenses 18 75 Total $ 1,037 $ 1,447

Leases (Tables)

Leases (Tables)	9 Months Ended
	Sep. 30, 2024
Leases
Schedule of Maturity of Operating and Finance Liabilities	The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of September 30, 2024: Schedule of Maturity of Operating and Finance Liabilities Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities Remainder of 2024 $ 245 $ 2 2025 998 7 2026 1,040 7 2027 944 7 2028 273 — Thereafter 138 — 2028 - - Thereafter - — Total undiscounted operating lease payments $ 3,638 $ 23 Less: Imputed interest 586 4 Present value of operating lease liabilities $ 3,052 $ 19 Weighted average remaining lease term in years 3.6 3.1 Weighted average discount rate 9.2 % 11.6 % The following table presents information about the amount and timing of liabilities arising from the Company’s operating leases and finance leases as of December 31, 2023: Maturity of Lease Liabilities Operating Lease Liabilities Finance Lease Liabilities 2024 $ 956 $ 7 2025 998 7 2026 1,040 7 2027 944 7 2028 273 — Thereafter 138 - Total undiscounted operating lease payments $ 4,349 $ 28 Less: Imputed interest 816 5 Present value of operating lease liabilities $ 3,533 $ 23 Weighted average remaining lease term in years 4.3 3.9 Weighted average discount rate 9.2 % 11.6 %

Stockholders_ Equity (Tables)

Stockholders’ Equity (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Shareholder Equity Warrants Outstanding	The following table summarizes the changes in warrants outstanding for the nine months ended September 30, 2024: Schedule of Shareholder Equity Warrants Outstanding Shares Outstanding at December 31, 2023 - Issued 666,667 Exercised - Tendered - Expired - Outstanding at September 30, 2024 666,667
Schedule of Anti-dilutive Securities Excluded from Computation of Earning Per Share	Schedule of Anti-dilutive Securities Excluded from Computation of Earning Per Share As of September 30, 2024 2023 Stock options 872,063 664,689 Warrants 666,667 — Total 1,538,730 664,689

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	9 Months Ended
	Sep. 30, 2024
Equity [Abstract]
Schedule of Components of Accumulated Other Comprehensive Loss	The following table summarizes the changes in accumulated other comprehensive loss by component during the nine months ended September 30, 2024 and 2023: Schedule of Components of Accumulated Other Comprehensive Loss Net Unrealized Gain/(Loss) on Available-for-Sale Securities Accumulated Other Comprehensive Loss Balance, December 31, 2023 $ (221 ) $ (221 ) Net unrealized gain on securities available-for-sale 221 221 Balance, September 30, 2024 $ — $ — Balance, December 31, 2022 $ (824 ) $ (824 ) Net unrealized gain on securities available-for-sale 465 465 Balance, September 30, 2023 $ (359 ) $ (359 )

Stock-based Compensation (Table

Stock-based Compensation (Tables)	9 Months Ended
	Sep. 30, 2024
Share-Based Payment Arrangement [Abstract]
Schedule of Recognized Stock-Based Compensation	The Company recognized stock-based compensation expense (options and restricted share grants) in its condensed consolidated statements of operations as follows: Schedule of Recognized Stock-Based Compensation Three Months Ended September 30, Nine Months Ended September 30, 2024 2023 2024 2023 Research and Development $ 387 $ 507 $ 1,212 $ 1,576 General and Administrative 578 689 1,739 2,100 Total $ 965 $ 1,196 $ 2,951 $ 3,676
Schedule of Stock Option Activity	The following table summarizes the activity for Company’ stock options for the nine months ended September 30, 2024: Schedule of Stock Option Activity Stock Options Outstanding at December 31, 2023 934,243 Granted — Exercised — Forfeited (18,649 ) Expired (43,531 ) Outstanding at September 30, 2024 872,063

Liquidity, Plan of Operations_2

Liquidity, Plan of Operations and Going Concern (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Accumulated deficit	$ 191,391		$ 191,391		$ 175,573
Net loss	4,275	$ 6,055	15,818	$ 17,628
Cash and cash equivalents	10,295	6,407	10,295	6,407	4,787	$ 6,830
Marketable securities	500		500		8,969
Restricted cash	$ 250	$ 250	$ 250	$ 250	$ 250	$ 250

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details Narrative)	Aug. 30, 2024
Accounting Policies [Abstract]
Stockholders' equity, reverse stock split	1-for-50 reverse stock split

Schedule of Cash, Cash Equivale

Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023	Sep. 30, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Cash and cash equivalents	$ 10,295	$ 4,787	$ 6,407	$ 6,830
Restricted cash included in current/non-current assets	250	250	250	250
Cash, cash equivalents and restricted cash in the statement of cash flows	$ 10,545	$ 5,037	$ 6,657	$ 7,080

Schedule of Marketable Debt Sec

Schedule of Marketable Debt Securities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost	$ 500	$ 9,190
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax		(221)
Debt Securities, Available-for-Sale	500	8,969
Corporate Debt Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost	500
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale	$ 500
US Treasury Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost		999
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax		(3)
Debt Securities, Available-for-Sale		996
US Government Agencies Debt Securities [Member]
Debt Securities, Held-to-Maturity, Allowance for Credit Loss [Line Items]
Debt Securities, Available-for-Sale, Amortized Cost		8,191
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax		(218)
Debt Securities, Available-for-Sale		$ 7,973

Cash, Cash Equivalents, Restr_3

Cash, Cash Equivalents, Restricted Cash and Marketable Debt Securities (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023	Dec. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Restricted cash	$ 250	$ 250	$ 250	$ 250	$ 250	$ 250
Unrealized gain on securities available-for-sale	51	$ 155	221	$ 465
Accumulated unrealized losses					$ 221

Schedule of Fair Value Measurem

Schedule of Fair Value Measurement of Assets and Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total	$ 500	$ 8,969
Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total		996
Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total	500	7,973
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total
Corporate Debt Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total	500
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total	500
Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total
US Treasury Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total		996
US Treasury Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total		996
US Treasury Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total
US Treasury Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total
US Government Agencies Debt Securities [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total		7,973
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total		7,973
US Government Agencies Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Total

Schedule of Leasehold Improveme

Schedule of Leasehold Improvements and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Leasehold improvements and equipment, gross	$ 3,618	$ 3,618
Less: accumulated depreciation and amortization	1,970	1,695
Leasehold improvements and equipment, net	1,648	1,923
Equipment [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements and equipment, gross	2,463	2,463
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Leasehold improvements and equipment, gross	$ 1,155	$ 1,155

Leasehold Improvements and Eq_3

Leasehold Improvements and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization expenses	$ 90	$ 98	$ 275	$ 288
Purchase of equipment and leasehold improvements				$ 218

Schedule of Accrued Expenses (D

Schedule of Accrued Expenses (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Payables and Accruals [Abstract]
Payroll and incentives	$ 720	$ 1,176
General and administrative expenses	299	196
Research and development expenses	18	75
Total	$ 1,037	$ 1,447

Schedule of Maturity of Operati

Schedule of Maturity of Operating and Finance Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2024	Dec. 31, 2023
Leases
Operating Lease Liabilities, Remainder of Fiscal Year	$ 245
Finance Lease Liabilities, Remainder of Fiscal Year	2
Operating Lease Liabilities, Year One	998	$ 956
Finance Lease Liabilities, Year One	7	7
Operating Lease Liabilities, Year Two	1,040	998
Finance Lease Liabilities, Year Two	7	7
Operating Lease Liabilities, Year Three	944	1,040
Finance Lease Liabilities, Year Three	7	7
Operating Lease Liabilities, Year Four	273	944
Finance Lease Liabilities, Year Four		7
Operating lease Liabilities, Year After Four	138
Finance Lease Liabilities, Year After Four
Operating lease Liabilities, Year Five		273
Finance Lease Liabilities, Year Five
Operating Lease Liabilities, Thereafter		138
Finance Lease Liabilities, Thereafter
Total undiscounted operating lease payments	3,638	4,349
Total undiscounted finance lease payments	23	28
Operating Lease Liabilities, less: Imputed interest	586	816
Finance Lease Liabilities, less: Imputed interest	4	5
Present value of operating lease liabilities	3,052	3,533
Present value of finance lease liabilities	$ 19	$ 23
Operating Lease Liabilities, weighted average remaining lease term in years	3 years 7 months 6 days	4 years 3 months 18 days
Finance Lease Liabilities, weighted average remaining lease term in years	3 years 1 month 6 days	3 years 10 months 24 days
Operating Lease Liabilities, weighted average discount rate	9.20%	9.20%
Finance Lease Liabilities, weighted average discount rate	11.60%	11.60%

Leases (Details Narrative)

Leases (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Leases
Operating lease option to extend, description			Some leases include purchase, termination or extension options for one or more years.
Remaining lease term	12 months		12 months
Operating lease interest expense	$ 225	$ 225	$ 677	$ 677
Operating lease right-of-use assets	152	139	446	406
Finance lease interest expense	1	0	2	2
Finance lease right-of-use assets	$ 1	$ 2	$ 4	$ 7

Revenue Recognition, Collabor_2

Revenue Recognition, Collaboration Agreements and Other (Details Narrative) - USD ($) $ in Thousands			3 Months Ended			9 Months Ended
	Apr. 08, 2022	Dec. 12, 2019	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023
Revenue							$ 1,096
BioNTech Agreement [Member]
Fees received	$ 2,750
Deferred revenue	$ 2,750
Revenue recognized					$ 688
Revenue					$ 375
Genentech Feasibility Study Agreement [Member]
Revenue		$ 33
Genentech Feasibility Study Agreement [Member] | Three Molecules [Member]
Revenue recognized		$ 100
Genentech Feasibility Study Agreement [Member] | Genentech [Member]
Agreement description		Genentech paid the Company a total of $100 for the development of three molecules, or $33 per molecule, which is being recognized upon the Company fulfilling its obligations for each molecule under the Genentech Agreement.

Schedule of Shareholder Equity

Schedule of Shareholder Equity Warrants Outstanding (Details)	9 Months Ended
	Sep. 30, 2024 shares
Equity [Abstract]
Shares outstanding, beginning
Shares issued	666,667
Shares exercised
Shares tendered
Shares expired
Shares outstanding, ending	666,667

Schedule of Anti-dilutive Secur

Schedule of Anti-dilutive Securities Excluded from Computation of Earning Per Share (Details) - shares	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	1,538,730	664,689
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	872,063	664,689
Warrant [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share, amount	666,667

Schedule of Components of Accum

Schedule of Components of Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Equity [Abstract]
Net Unrealized Gains/(Loss) on Available-for-Sale Securities, Beginning Balance			$ (221)	$ (824)
Accumulated Other Comprehensive Loss, Beginning Balance			(221)	(824)
Net Unrealized Gains/(Loss) on Available-for-Sale Securities, Net unrealized loss on securities available-for-sale	$ 51	$ 155	221	465
Accumulated Other Comprehensive Loss, Net unrealized loss on securities available-for-sale			221	465
Net Unrealized Gains/(Loss) on Available-for-Sale Securities, Ending Balance		(359)		(359)
Accumulated Other Comprehensive Loss, Ending Balance		$ (359)		$ (359)

Stockholders_ Equity (Details N

Stockholders’ Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	9 Months Ended
		Apr. 05, 2024	Feb. 29, 2024	Sep. 30, 2024	Aug. 30, 2024	Aug. 29, 2024	Dec. 31, 2023
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized				250,000,000			250,000,000
Common stock per share				$ 0.0001			$ 0.0001
Common stock, shares issued				5,086,985			4,345,291
Common stock, shares outsatnding				5,086,985			4,345,291
Net of proceeds shares		$ 10,000
Net proceeds from sale of common stock		$ 9,190
Reverse Stock Split [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock, shares authorized					250,000,000	500,000,000
Common stock per share					$ 0.0001
Common stock, shares issued					5,086,985	250,816,164
Common stock, shares outsatnding					5,086,985	250,816,164
Common Stock [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Issuance of common stock and warrants in public offering, net of stock issuance cost	[1]			671,033
Common Stock [Member] | BTIG, LLC [Member] | At-The-Market Sales Agreement [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Net proceeds from sale of common stock			$ 54
Number of shares sold			4,366,000
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Common stock per share		$ 15
Issuance of common stock and warrants in public offering, net of stock issuance cost		666,667
Outstanding warrants to purchase of shares				666,667
Exercise price per share				$ 17.50
Warrants exercisable term		5 years
[1]Adjusted to reflect the impact of the 1-for-50 reverse stock split

Schedule of Recognized Stock-Ba

Schedule of Recognized Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 965	$ 1,196	$ 2,951	$ 3,676
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	387	507	1,212	1,576
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Share-based compensation expense	$ 578	$ 689	$ 1,739	$ 2,100

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details)	9 Months Ended
	Sep. 30, 2024 shares
Share-Based Payment Arrangement [Abstract]
Stock Options, Outstanding	934,243
Granted
Exercised
Forfeited	(18,649)
Expired	(43,531)
Stock Options, Outstanding	872,063

Stock-based Compensation (Detai

Stock-based Compensation (Details Narrative) $ in Thousands	9 Months Ended
	Sep. 30, 2024 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Term of the award	The term of the Plan was for 10 years.
Unrecognized share based compensation | $	$ 4,597
Unrecognized share based compensation, recognition period	2 years 2 months 12 days
2013 Equity Compensation Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Stock awards including restricted stock options grants awards issued and exercised | shares	965,678

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)	1 Months Ended
	Oct. 31, 2024 USD ($)
Subsequent Event [Member]
Subsequent Event [Line Items]
Severance costs	$ 2,150